Trial Profile
A pivotal phase II trial investigating the efficacy of OTX-101 in patients with keratoconjunctivitis sicca (dry eye disease)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Registrational; Therapeutic Use
- Sponsors Auven Therapeutics
- 20 Nov 2015 New trial record
- 13 Nov 2015 According to an Auven Therapeutics media release, the company expects to begin enrollment in this trial in early 2016. If this results of this study are positive, the company expects to submit an NDA for OTX-101 [Seciera] for the treatment of dry eye disease in early 2017.